• Explore /
  • Poster
  • / Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr).

Prognostic role of beta-2 microglobulin (B2M) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) patients (pts) treated with ibrutinib (ibr).

Abstract Poster

Authors

null

William G. Wierda

The University of Texas MD Anderson Cancer Center, Houston, TX

William G. Wierda , Jennifer R. Brown , Stephan Stilgenbauer , Steven Coutre , John C. Byrd , Anthony R. Mato , Constantine Tam , Jacqueline C. Barrientos , Ulrich Jäger , Stephen Devereux , Florence Cymbalista , Paul M. Barr , Claire Dearden , Marco Montillo , Carol Moreno , Emily Y. Liu , Anita Szoke , James P. Dean , Susan Mary O'Brien

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Chronic Lymphocytic Leukemia (CLL) and Hairy Cell

Clinical Trial Registration Number

NCT01578707 and NCT01744691

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7521)

DOI

10.1200/JCO.2018.36.15_suppl.7521

Abstract #

7521

Poster Bd #

158

Abstract Disclosures

Similar Posters

First Author: John C. Byrd

First Author: Jennifer Ann Woyach

First Author: John C. Byrd

First Author: Kerry Anne Rogers